Matthew Leigh Sherman

机构：Deciphera Pharmaceuticals (United States) · ORCID：0009-0009-4646-5819

发表论文 192 篇 · 总被引 11219 次 · h-index 47

代表论文

• Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial (2022 · Journal of Clinical Oncology · 被引 121)
• Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2024 · The Lancet · 被引 79)
• Ripretinib versus sunitinib in gastrointestinal stromal tumor: ctDNA biomarker analysis of the phase 3 INTRIGUE trial (2024 · Nature Medicine · 被引 61)
• Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study (2021 · The Oncologist · 被引 34)
• CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of Vimseltinib (2024 · Clinical Cancer Research · 被引 30)
• The INSIGHT study: a randomized, Phase III study of ripretinib versus sunitinib for advanced gastrointestinal stromal tumor with KIT exon 11 + 17/18 mutations (2024 · Future Oncology · 被引 19)